News from Boehringer Ingelheim Vetmedica, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 18, 2017, 09:00 ET Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim announced today that BI 695501, its adalimumab biosimilar candidate to Humira®*, has been accepted for regulatory review by...


Dec 06, 2016, 06:42 ET Novo medicamento da Boehringer Ingelheim para câncer de pulmão bloqueia de forma irreversível a multiplicação das células cancerígenas

A Boehringer Ingelheim, uma das principais farmacêuticas do mundo focada em pesquisa para soluções terapêuticas inovadoras, lança no Brasil o...


Oct 26, 2016, 08:00 ET Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study

Boehringer Ingelheim today announced top-line results from the pivotal Phase III clinical study of BI 695501, a biosimilar candidate to...


Oct 24, 2016, 08:00 ET Efficacy of Ofev® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST

At CHEST 2016, two post-hoc pooled analyses of the Phase III INPULSIS® trials were presented that further demonstrate the efficacy of Ofev®...


Oct 09, 2016, 08:05 ET Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO

Boehringer Ingelheim today announced results from the LUX-Lung 7 trial that directly compared the efficacy and safety of second-generation...


Sep 28, 2016, 08:00 ET Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics

 Boehringer Ingelheim and ViraTherapeutics today announced a long-term collaboration to jointly develop a next generation oncolytic virus...


Sep 27, 2016, 08:30 ET Boehringer Ingelheim Named to the 2016 Working Mother 100 Best Companies List

Boehringer Ingelheim announced today that it has been named to Working Mother magazine's annual 100 Best Companies list for the fifth consecutive...


Jun 02, 2016, 08:00 ET Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

 Boehringer Ingelheim has initiated the ELUXA trial program, designed to further investigate the therapeutic potential of olmutinib (BI...


Feb 29, 2016, 15:25 ET Boehringer Ingelheim lança medicamento inédito para doença rara e revoluciona panorama de tratamento da Fibrose Pulmonar Idiopática

 A Boehringer Ingelheim, uma das 20 principais farmacêuticas do mundo, anuncia o lançamento de OFEV® (nintedanibe) no Brasil,...


Dec 21, 2015, 08:00 ET Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its...


Dec 02, 2015, 08:00 ET Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

 Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a collaboration focused on developing innovative...


Feb 02, 2015, 05:00 ET Leading Animal Health Company, Boehringer Ingelheim Vetmedica, Inc., Announces Website Redesign

Today, Boehringer Ingelheim Vetmedica, Inc. (BIVI), the 5th largest animal health company in the United States, announces the launch of its...


Jan 12, 2015, 08:00 ET The Lancet Oncology publishes phase III data showing Gilotrif® (afatinib) extends overall survival in lung cancer patients whose tumors have the most common EGFR mutation compared with chemotherapy

 Boehringer Ingelheim today announced overall survival (OS) results were published in The Lancet Oncology from two independent Phase III...


Nov 03, 2014, 08:00 ET FDA Study of Medicare Patients Reaffirms Safety and Efficacy Profile of Pradaxa® (dabigatran etexilate mesylate) for NVAF

 A U.S. Food and Drug Administration (FDA) study of more than 134,000 Medicare patients found that Pradaxa® (dabigatran etexilate...


Oct 21, 2014, 08:00 ET Boehringer Ingelheim initiates global Phase III study investigating nintedanib in patients with colorectal cancer

 Boehringer Ingelheim today announced enrollment of the first patient in a new global Phase III study in patients with metastatic colorectal...


Oct 20, 2014, 15:00 ET OFEV® (nintedanib) Now Available in the United States

 Boehringer Ingelheim Pharmaceuticals, Inc. has announced that OFEV® (nintedanib) capsules are now commercially available in the United...


Sep 26, 2014, 12:30 ET Boehringer Ingelheim Statement on FDA Drug Development Public Meeting for Idiopathic Pulmonary Fibrosis (IPF)

RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S. Food and Drug Administration (FDA) for conducting...


Aug 01, 2014, 08:05 ET FDA Approves Boehringer Ingelheim's Striverdi® Respimat® (olodaterol) Inhalation Spray for Maintenance Treatment of COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi® Respimat® (olodaterol)...


Jul 23, 2014, 14:00 ET Benefits and Safety of Pradaxa® (dabigatran etexilate mesylate) Repeatedly Confirmed

 Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ)...


Jul 08, 2014, 07:38 ET Boehringer Ingelheim's volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood

 Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in...


May 28, 2014, 08:00 ET Boehringer Ingelheim Announces Comprehensive Settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) Litigation

 Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation...


May 21, 2014, 11:15 ET Boehringer Ingelheim Presents First Phase 3 Data on Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD

 Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the...


Jan 30, 2014, 12:30 ET Boehringer Ingelheim and Duke Clinical Research Institute Form Collaborative Partnership to Study the Natural History of Idiopathic Pulmonary Fibrosis (IPF)

 Boehringer Ingelheim Pharmaceuticals, Inc. and Duke Clinical Research Institute (DCRI) have formed a unique collaborative relationship to...


Nov 07, 2013, 06:00 ET New Online Map Provides Resource for Pet Owners in At-Risk Leptospirosis Environments

A new interactive map of the United States based on an online survey of veterinarians launched on Leptoinfo.com helps to highlight the...